The sarcastic comment that “escaping from the KOSPI (Korean stock market) is a matter of intelligence” has become a trend for some time. Although the so-called “Korea discount” is not new, the distrust of the Korean stock market among individual investors has been rising recently.

Pharmaceutical, biotech, and healthcare stocks are no exception. In fact, compared to other sectors, pharma bio, and healthcare stocks are even more shunned by these individual investors.

According to the Korea Exchange, individual investors sold more than KRW 1.5 trillion worth of pharma bio and healthcare stocks last year. This leaves a bitter aftertaste, considering how these individual investors made n